Personalis, Inc. (PSNL)

NASDAQ: PSNL · IEX Real-Time Price · USD
2.06
+0.14 (7.29%)
At close: Jun 2, 2023, 4:00 PM
2.00
-0.06 (-2.91%)
After-hours: Jun 2, 2023, 7:55 PM EDT
7.29%
Market Cap 96.37M
Revenue (ttm) 68.68M
Net Income (ttm) -113.77M
Shares Out 46.78M
EPS (ttm) -2.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 405,483
Open 1.96
Previous Close 1.92
Day's Range 1.95 - 2.07
52-Week Range 1.73 - 5.58
Beta 1.41
Analysts Strong Buy
Price Target 7.00 (+239.81%)
Earnings Date May 3, 2023

About PSNL

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT D... [Read more]

Sector Healthcare
IPO Date Jun 20, 2019
Employees 395
Stock Exchange NASDAQ
Ticker Symbol PSNL
Full Company Profile

Financial Performance

In 2022, Personalis's revenue was $65.05 million, a decrease of -23.92% compared to the previous year's $85.49 million. Losses were -$113.32 million, 73.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 239.81% from the latest price.

Price Target
$7.0
(239.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023

FREMONT, Calif.--(BUSINESS WIRE)--Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023.

3 days ago - Business Wire

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

FREMONT, Calif. & KASHIWA, Japan & OSAKA, Japan--(BUSINESS WIRE)--Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer.

2 weeks ago - Business Wire

Personalis Reports First Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and...

1 month ago - Business Wire
}

Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, ABRCC, and Criterium announce major prospective clinical trial.

1 month ago - Business Wire

Personalis to Announce First Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results o...

1 month ago - Business Wire

Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd An...

2 months ago - Business Wire

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

FREMONT, Calif. & LONDON--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK's Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announ...

2 months ago - Business Wire

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual...

2 months ago - Business Wire
}

Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Na...

Other symbols: AZN
3 months ago - Business Wire

Personalis Appoints Christopher Hall as Chief Executive Officer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as C...

3 months ago - Business Wire

Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended Dec...

3 months ago - Business Wire

Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 fina...

4 months ago - Business Wire

Personalis to Participate at Upcoming Investor Conferences

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor confe...

4 months ago - Business Wire
}

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenge...

Other symbols: MRNA
4 months ago - Business Wire

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full ...

5 months ago - Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, betwee...

6 months ago - Business Wire

Personalis Announces CEO Retirement and Transition

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of di...

6 months ago - Business Wire

Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer

MENLO PARK, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based ...

6 months ago - Business Wire

Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34th Annual Piper Sandler...

6 months ago - Business Wire

Personalis Reports Third Quarter 2022 Financial Results

MENLO PARK, Calif.

7 months ago - Business Wire

Personalis to Announce Third Quarter 2022 Financial Results

MENLO PARK, Calif.

8 months ago - Business Wire

Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on a...

8 months ago - Business Wire

Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual ...

9 months ago - Business Wire